Dan Kirby | Chief Commercial Officer
Iovance Biotherapeutics

Mr. Kirby joined Iovance in February 2025 as Chief Commercial Officer, bringing deep experience in commercial operations, including cell therapy. Prior to joining Iovance, Mr. Kirby led global commercial strategy and operations for an emerging cell therapy platform of products as Chief Commercial Officer of Orca Bio. From 2018 to 2020, he served as Chief Commercial Officer at Omeros Corporation, overseeing U.S. and EU launch readiness for narsoplimab targeting complications post hematopoietic stem cell transplantation as well as all commercial activities for their marketed product, Omidria. Previously, he led market access, reimbursement and marketing efforts for CAR T products as Vice President and Head of US Cell and Gene at Celgene (now Bristol-Myers Squibb). He joined Celgene following the acquisition of Juno Therapeutics, where he was Vice President of Marketing and Market Access. Earlier in his career, Mr. Kirby was Head of Marketing for Medivation (now Pfizer) and held various commercial roles of increasing responsibility during a 14-year tenure at Amgen.